pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

847 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • <![CDATA[Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC]]>
    <![CDATA[Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer]]>
    <![CDATA[Phase 1/2 data showed an ORR of 35% with daraxonrasib in second-line RAS G12-mutated pancreatic ductal adenocarcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.]]>
    <![CDATA[Researchers at Sylvester identified populations in the US where this cancer may be largely preventable by addressing mother‑to‑child transmission of the virus.]]>
← prev
page 28 of 34
next →
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • EnGene's shares crash on updated pivotal bladder cancer data
    EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech'…
    Endpoints · 2mo ago↗ source
  • Are health insurers out of the woods after a tough 2025?
    Last year, health insurer after health insurer slashed or withdrew their profit outlooks after being sucker-punched by high medical costs. This year is shaping up ...
    Endpoints · 2mo ago↗ source
  • Blackstone puts $250M into Anagram to tackle cystic fibrosis complication
    Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…
    Endpoints · 2mo ago↗ source
  • <![CDATA[FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease]]>
    <![CDATA[The FDA and Atara Biotherapeutics completed a Type A meeting to discuss the CRL for tabelecleucel in post-transplant lymphoproliferative disease.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies]]>
    <![CDATA[Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>
    onclive · 2mo ago↗ source
  • Entrada stock falls on Duchenne data; Wegovy expands access
    Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...
    Endpoints · 2mo ago↗ source
  • Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany
    Plus, news about FDA's one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production in Juncos, which was establishe…
    Endpoints · 2mo ago↗ source
  • Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
    There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an…
    Endpoints · 2mo ago↗ source
  • <![CDATA[Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026]]>
    <![CDATA[Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.]]>
    onclive · 2mo ago↗ source
  • Pennsylvania sues AI chatbot company for posing as a licensed doctor
    The state of Pennsylvania has sued Character.AI, a startup that lets users chat with different AI-generated personas, for illegally presenting a chatbot as a licensed doctor in the state. This is…
    Endpoints · 2mo ago↗ source
  • <![CDATA[EGFR-Targeted Therapy Sequencing After Resistance in NSCLC]]>
    <![CDATA[Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations]]>
    <![CDATA[Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA]]>
    <![CDATA[Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response]]>
    <![CDATA[Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Reigniting Your Curiosity During Fellowship ]]>
    <![CDATA[Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.]]>
    onclive · 2mo ago↗ source
  • Angelini fortifies neurology portfolio with $4.1B buyout of Catalyst
    Angelini Pharma is spending $4.1 billion to buy Catalyst Pharmaceuticals and its trio of FDA-approved treatments for rare neurological diseases. The buyout will add three medicines to Angelini’s…
    Endpoints · 2mo ago↗ source
  • <![CDATA[MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ]]>
    <![CDATA[R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]>
    <![CDATA[Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.]]>
    onclive · 2mo ago↗ source
  • Amgen, AbbVie say IRA negotiations impacted Q1 sales
    At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in th…
    Endpoints · 2mo ago↗ source